DRG/DIP分组方案调整
Search documents
医保按病种付费分组方案3.0版预计7月公布
第一财经· 2026-03-20 06:10
Core Viewpoint - The article discusses the upcoming upgrade of China's medical insurance payment reform, specifically the DRG/DIP 3.0 version grouping plan, which is expected to be announced in July 2026 and implemented nationwide by January 2027 [3][4]. Summary by Sections DRG/DIP 3.0 Version Adjustment - The National Healthcare Security Administration (NHSA) has initiated the DRG/DIP 3.0 version adjustment since July 2025, focusing on clinical factors such as age and comorbidities to refine grouping rules [3][6]. - The adjustment is based on real data from medical insurance settlements, extensive feedback from stakeholders, advancements in medical technology, and healthcare policy requirements [7][8]. Data Collection and Clinical Validation - A comprehensive database was created using approximately 1 billion case records from 2022 to mid-2025 to support the adjustment process [7]. - From July to November 2025, around 35,000 opinions were collected, with about 30,000 being valid, primarily addressing grouping rules and coding updates [8][9]. Collaboration and Expert Involvement - The adjustment process emphasizes close collaboration among various departments, including the NHSA, the National Health Commission, and the National Disease Control Bureau, to ensure the grouping plan aligns with clinical realities [9][10]. - Experts from diverse clinical fields participated in the validation process, ensuring a high level of authority and representation across different regions and institution types [9][10]. Key Findings from Clinical Validation - The first phase of clinical validation revealed a consensus on many opinions, indicating that the adjustment direction aligns well with clinical needs [11]. - Specific adjustments include the addition of rehabilitation groups in major disease categories and the separation of bilateral joint replacement surgeries into distinct categories to better reflect clinical practices [12][11]. Next Steps - The NHSA plans to conduct a second phase of clinical validation and data verification to finalize the 3.0 version grouping plan, which will be published following established procedures [13].